Hospital
Barrett Hospital Development Corporation
Barrett Hospital Development Corporation was paid $790K by Medicaid between Jan 2018 and Dec 2024, across 130 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoBARRETT HOSPITAL DEVELOPMENT CORPORATION
DILLON, MT 59725
DILLON, MT 59725
33aNPI1326042078assigned 06/10/2005
33bProvider typeCritical Access Hospital
28Total paid$790K
24GClaims132,619
24DCodes billed130
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Montana
Rank by total paid#6 of 25
Median peer was paid$185K
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,928 | $152K | |
| 2019 | 19,175 | $102K | |
| 2020 | 17,047 | $85K | |
| 2021 | 20,888 | $129K | |
| 2022 | 20,249 | $151K | |
| 2023 | 18,179 | $91K | |
| 2024incomplete | 13,153 | $81K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 4,687 | 4,137 | $168K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 3,851 | 3,115 | $119K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.9% | 5,668 | 3,641 | $63K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 3,099 | 2,217 | $55K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 817 | 738 | $46K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 5.7% | 1,523 | 1,386 | $45K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.1% | 1,056 | 980 | $33K |
| 80053 | Comprehensive metabolic panel | 2.5% | 9,827 | 8,110 | $20K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.3% | 518 | 490 | $18K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.3% | 2,099 | 761 | $18K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 2,325 | 1,912 | $17K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 356 | 316 | $16K |
118 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 5,427 | $14K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 10,241 | $12K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 2,426 | $11K |
| G0378 | Hospital observation service, per hour | 1.3% | 154 | $10K |
| 86140 | 1.2% | 4,392 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,556 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 753 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,312 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,939 | $6K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,306 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,997 | $4K |
| 83690 | <1% | 2,299 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,729 | $4K |
| 90837 | Psychotherapy session, about an hour | <1% | 113 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,382 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,371 | $3K |
| 81001 | <1% | 2,537 | $3K | |
| 87631 | <1% | 114 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,977 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,705 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 293 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,555 | $2K |
| 81003 | <1% | 1,600 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 224 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 280 | $2K |
| 73130 | <1% | 75 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,007 | $2K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 14 | $2K |
| 84484 | <1% | 1,484 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 102 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 599 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 590 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,366 | $1K |
| 80061 | Lipid panel | <1% | 1,583 | $1K |
| 84703 | <1% | 755 | $1K | |
| 97162 | <1% | 176 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 282 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 282 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 581 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,906 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,368 | $994.39 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 410 | $974.71 |
| 83605 | <1% | 874 | $938.09 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,392 | $914.03 |
| 84439 | <1% | 381 | $909.55 | |
| 73610 | <1% | 41 | $777.66 | |
| 85379 | <1% | 50 | $669.86 | |
| 73630 | <1% | 72 | $620.10 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 15 | $605.60 |
| 73110 | <1% | 32 | $572.40 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 402 | $556.29 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,750 | $536.40 |
| 85027 | <1% | 550 | $523.93 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 88 | $510.30 |
| 85610 | <1% | 1,612 | $398.83 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 71 | $385.19 |
| 81025 | <1% | 161 | $384.41 | |
| 87186 | <1% | 377 | $372.26 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 603 | $368.96 |
| 85652 | <1% | 227 | $359.16 | |
| J2704 | Injection, propofol, 10 mg | <1% | 343 | $351.55 |
| 83525 | <1% | 267 | $341.10 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 498 | $337.74 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 624 | $318.15 |
| 87486 | <1% | 87 | $310.50 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 12 | $293.96 |
| 90686 | <1% | 114 | $256.48 | |
| 80050 | General health panel | <1% | 16 | $246.60 |
| 87581 | <1% | 86 | $234.00 | |
| 87077 | <1% | 376 | $225.80 | |
| 73562 | <1% | 29 | $220.50 | |
| 96376 | <1% | 134 | $212.40 | |
| 86677 | <1% | 15 | $207.89 | |
| 97161 | <1% | 58 | $144.90 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 139 | $126.32 |
| 80305 | <1% | 69 | $119.69 | |
| 90688 | <1% | 73 | $111.37 | |
| 36416 | <1% | 362 | $104.40 | |
| 83735 | <1% | 206 | $95.39 | |
| 82728 | <1% | 27 | $83.70 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 15 | $68.63 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 30 | $48.36 |
| 85651 | <1% | 53 | $40.50 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 149 | $27.00 |
| 82962 | <1% | 36 | $24.30 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 167 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 88 | $0.00 |
| 85730 | 0% | 15 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 81 | $0.00 |
| 99308 | Subsequent nursing facility care, per day, straightforward | 0% | 53 | $0.00 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 0% | 30 | $0.00 |
| 86901 | 0% | 41 | $0.00 | |
| 87040 | 0% | 44 | $0.00 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 0% | 17 | $0.00 |
| 86803 | 0% | 16 | $0.00 | |
| 83880 | 0% | 34 | $0.00 | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | 0% | 12 | $0.00 |
| 87507 | 0% | 17 | $0.00 | |
| 86850 | 0% | 26 | $0.00 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 0% | 17 | $0.00 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 0% | 199 | $0.00 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 4,882 | $0.00 |
| 97533 | 0% | 326 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 12 | $0.00 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 167 | $0.00 |
| 86900 | 0% | 41 | $0.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 437 | $0.00 |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 0% | 34 | $0.00 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 0% | 35 | $0.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 19 | $0.00 |
| 90715 | 0% | 12 | $0.00 | |
| 99490 | Ccm add 20min | 0% | 64 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 28 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 12 | $0.00 |
| 76000 | 0% | 34 | $0.00 | |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 14 | $0.00 |
| 84702 | 0% | 18 | $0.00 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGIEM, TINA (CHIEF FINANCIAL OFFICER)